Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

Carlo Gambacorti‐Passerini, Laura Antolini, François‐Xavier Mahon, +25

JNCI Journal of the National Cancer Institute

Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia

Gianantonio Rosti, Francesca Palandri, Fausto Castagnetti, +20

Blood

Age and d<scp>PCR</scp> can predict relapse in <scp>CML</scp> patients who discontinued imatinib: The <scp>ISAV</scp> study

Silvia Mori, Elisabetta Vagge, Philipp le Coutre, +22

American Journal of Hematology

SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub

Rocco Piazza, Vera Magistroni, Sara Redaelli, +23

Nature Communications

Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib

Fabio Efficace, Michele Baccarani, Massimo Breccia, +22

Leukemia

Hematological MalignancyQuality Of LifeImportant FactorFatigue ManagementHealth-related Quality +9

Differences among young adults, adults and elderly chronic myeloid leukemia patients

Fabio Castagnetti, Gabriele Gugliotta, Michele Baccarani, +151

Annals of Oncology

Hematological MalignancyFamily MedicineYoung AdultsAgingHealth Policy +6

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study

Simona Soverini, Luana Bavaro, Caterina De Benedittis, +45

Blood

Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis

Francesco Di Raimondo, MP Azzaro, Sabrina Bagnato, +6

Leukemia

InflammationFibrosisAngiogenesisHematologyMyeloid Neoplasia +7

Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib

Fausto Castagnetti, Gabriele Gugliotta, Massimo Breccia, +22

Leukemia

Hematological MalignancyMedicineMixed-phenotype Acute LeukemiaHematologyLong-term Outcome +5

Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP

Michele Baccarani, Elisabetta Abruzzese, Vincenzo Accurso, +58

Blood Advances

Mixed-phenotype Acute LeukemiaPathologyCell Replacement TherapyLogistic AnalysisMyeloid Neoplasia +14